EU pushes Bayer PAH drug Adempas further down the road

Germany-based Bayer got an added boost today for its lung disease drug Adempas when the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval for the treatment of both chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension (PAH). The FDA had granted approval for the indications in October. It's the first of a new generation of drugs for PAH, and it's a pill rather than an injectable, which gives it a convenience advantage over some older meds. Analysts figure Adempas can top $700 million by 2018, and some see it leading the pulmonary hypertension market, but rivals are on the way. Announcement | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.